prikaz prve stranice dokumenta Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease
  Download
PDF 869.5 KB
Scientific paper - Review paper
Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease
Drugs & Aging, 33 (2016), 11; 787-808. https://doi.org/10.1007/s40266-016-0407-9
Osmanović-Barilar, Jelena; Šalković-Petrišić, Melita

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Osmanović Barilar, J. & Šalković Petrišić, M. (2016). Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease. Drugs & Aging, 33. (11), 787-808. doi: 10.1007/s40266-016-0407-9

Osmanović Barilar, Jelena and Melita Šalković Petrišić. "Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease." Drugs & Aging, vol. 33, no. 11, 2016, pp. 787-808. https://doi.org/10.1007/s40266-016-0407-9

Osmanović Barilar, Jelena and Melita Šalković Petrišić. "Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease." Drugs & Aging 33, no. 11 (2016): 787-808. https://doi.org/10.1007/s40266-016-0407-9

Osmanović Barilar, J. and Šalković Petrišić, M. (2016) 'Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease', Drugs & Aging, 33(11), pp. 787-808. doi: 10.1007/s40266-016-0407-9

Osmanović Barilar J, Šalković Petrišić M. Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease. Drugs & Aging [Internet]. 2016 November [cited 2024 November 22];33(11):787-808. doi: 10.1007/s40266-016-0407-9

J. Osmanović Barilar and M. Šalković Petrišić, "Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease", Drugs & Aging, vol. 33, no. 11, pp. 787-808, November 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:631932. [Accessed: 22 November 2024]

Metadata
Title (english)Evaluating the role of hormone therapy in postmenopausal women with Alzheimer's disease
AuthorJelena Osmanović-Barilar
AuthorMelita Šalković-Petrišić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Hormone therapy (HT) is prescribed during or after menopausal transition to replace the decline in estrogen and progesterone levels. While some studies indicate that estrogen and progesterone depletion in postmenopausal women might carry a significant risk for developing sporadic Alzheimer's disease (sAD), which may be reduced by HT, recent clinical trials oppose this beneficial effect. This review points to possible reasons for these mixed data by considering the issues of both preclinical and clinical trials, in particular, the representativeness of animal models, timing of HT initiation, type of HT (different types of estrogen compounds, estrogen monotherapy vs. estrogen-progesterone combined therapy), mode of drug delivery (subcutaneous, transdermal, oral, or intramuscular), and hormone dosage used, as well as the heterogeneity of the postmenopausal population in clinical trials (particularly considering their sAD stage, anti-AD therapy, and hysterectomy status). Careful planning of future preclinical and clinical HT interventional studies might help to elucidate the effect of HT on cognitive status in postmenopausal women with sAD, which will eventually contribute to more effective sAD prevention and treatment.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleDrugs & Aging
Numberingvol. 33, no. 11, pp. 787-808
p-ISSN1170-229X
DOIhttps://doi.org/10.1007/s40266-016-0407-9
URN:NBNurn:nbn:hr:105:631932
Publication2016-11
Document URLhttps://doi.org/10.1007/s40266-016-0407-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:59:54